# Independent final CHNS case review

Reviewer: `/root/chns_f2_review`. This review follows the released primary evaluation and one completed independent numerical recomputation. The CHNS target is now revealed and closed to further confirmation-stage fitting.

**Decision: the pilot supports limited directional analytical utility of evidence-guided whole-cohort generation. It does not establish reliable effect-size recovery, population-distribution recovery, or benefit from source-feedback revision. Close this case and preserve all outcomes.**

## Numerical verification and execution history

The independent implementation decoded the approved four source files, independently prepared the linked common denominator, recomputed all three OLS projections and community CR1/t intervals with statsmodels, and checked every planned generated slot and diagnostic against the primary report. It found **zero disagreements** under the prespecified numerical tolerance `rtol=1e-8`, `atol=1e-10`. That tolerance concerns computation only, not scientific equivalence.

| Artifact | SHA-256 |
| --- | --- |
| Completed primary report | `55c307e230d1d59eded5d5af0dd15b0ca376d8a2b045cb00621c5b0e5409794f` |
| Independent recomputation report | `be246b4f33b36d54b981d8b2a5d92ce90e48843861f948522a01ac34948e9d58` |
| Independent script | `be03a4c63ce577ba93bd37600cddda528a738917e33829b0d0c950c936ea652a` |
| Explicit recomputation authorization | `bdf0dd5d9c2b03f4f97dbfadb108fbfb28f3da916bae4426ab964c7d265dedde` |

The first absolute-path invocation failed before the metadata gate/reservation with an import-path error. The coordinator explicitly reviewed and authorized an environment-only continuation with `PYTHONPATH` set to the project root; script, authorization, plan and primary-report bytes remained unchanged. `INDEPENDENT_LAUNCH_FAILURE.md` preserves that failure. The subsequent gated recomputation completed in about 3.9 seconds, without a post-reservation retry. No generator, calibration or additional scientific test ran.

The independent implementation shares the SAS decoder and frozen definitions with the primary implementation; only the primary metadata permission gate is reused. Preparation, OLS/CR1/t and numerical comparisons are separate. Agreement supports the correctness of these calculations, not the truth of the underlying biological/transport assumptions.

## Reference and all prespecified results

The released reference contains **6,631 common-complete-case participants aged 35-74**, in **218 communities**, after the fixed linkage/measurement policy. From 9,549 biomarker records, 9,516 linked through examination/survey/master metadata; 6,809 met age/gender eligibility before the full common-denominator requirement. There were no nonfinite or nonpositive glycemic measurements triggering the fixed interpretation gate in the applicable reference preparation/analysis. These are availability-selected, unweighted analyses, not national-population estimates or known population truth. The nominal community intervals depend on the specified clustering assumptions.

The table gives the reference coefficient and nominal 95% interval, then the full range across all three seeds for each independently constructed generator. Initial and retained stages have the same values and must not be counted as additional independent results.

| Fixed analytical quantity | Reference coefficient [95% CR1/t interval] | C1, all three seeds | C2, all three seeds |
| --- | --- | --- | --- |
| E1: BMI coefficient in HbA1c ~ age + female + BMI; percentage points per kg/m² | 0.054946 [0.045726, 0.064166] | 0.016537-0.017933 | 0.020494-0.021327 |
| E2: glucose coefficient in HbA1c ~ age + female + glucose; percentage points per mmol/L | 0.402093 [0.371286, 0.432900] | 0.293471-0.301090 | 0.356062-0.398794 |
| E3: age coefficient in HbA1c ~ female + BMI + glucose + age; percentage points per year | 0.008107 [0.006387, 0.009827] | 0.005284-0.006337 | 0.002714-0.003843 |

All three reference intervals exclude zero positively. Every generated coefficient is positive across all three seeds in both constructions. This meets the frozen limited directional criterion. It is not evidence that all generated scientific relationships are realistic, nor are these unknown biological discoveries: analogous source relationships and assumption-dependent joint structure were already supplied. The exact target projections were held from feedback, but related source analyses were available.

All generated point estimates are below their corresponding reference point estimates. Because reference direction is supported, the prespecified descriptive generated/reference ratios are available:

| Quantity | C1 ratio range | C2 ratio range |
| --- | --- | --- |
| E1 | 0.301-0.326 | 0.373-0.388 |
| E2 | 0.730-0.749 | 0.886-0.992 |
| E3 | 0.652-0.782 | 0.335-0.474 |

E1 therefore has substantial magnitude underrepresentation in both constructions despite a stable positive sign. C2 is descriptively closer for E2; its first two seeds fall inside the reference interval and the third does not. C2 is farther away for E3 than C1. No C1 estimate, and no C2 E1/E3 estimate, lies inside its corresponding reference interval. Interval membership is descriptive only; this review does not turn it into an equivalence test or a test of generated-minus-reference uncertainty. C1's highest E3 estimate is close to the interval boundary, which should remain visible rather than be reduced to a binary success/failure label.

There is no justified overall winner, best-seed selection or composite success rate. C2's closer E2 result cannot excuse its poorer E3 magnitude. The reference interval is not a confidence interval for each generated point, and seed spread captures conditional simulation variation rather than source, structural or migration uncertainty.

## Diagnostics and analytical implications

The main distributions illustrate why preserving means or one relationship is not enough. Reference HbA1c mean/SD are 5.675/0.954. C1's means are 5.738-5.744 but SDs only 0.719-0.736; C2's means are 5.695-5.723 but SDs only 0.534-0.578. Thus fairly close mean values coexist with markedly narrower generated variation relative to this sample. These are descriptive sample differences; no prespecified inference for mean/SD equality was performed, and they are not declared known population biases.

The glucose-HbA1c reference Pearson/Spearman correlations are approximately **0.661/0.361**. C1 gives Pearson 0.533-0.554 and Spearman 0.516-0.545; C2 gives Pearson 0.666-0.685 and Spearman 0.478-0.483. In this sample, C2's near-reference Pearson values coexist with appreciably higher rank correlations and weaker age/BMI projection magnitudes. This directly demonstrates that agreement with one aggregate association is insufficient to establish reusable joint-distribution accuracy. It does not identify the cause: source selection, population transport, tail/mixture assumptions, age/sex composition and conditional structure were not separately intervened on here.

Those observations may inform a future prospectively designed mechanism question, but are now **post-reveal findings**. They cannot be used to modify this generator and then call the same CHNS sample a new confirmation. No additional model, synthetic cohort or source search is authorized by this review.

## Retained stages and contribution boundary

Both Agents reviewed all three source-feedback reports and chose to retain their scientific models. All initial/retained seed pairs have identical output hashes. The twelve executed slots therefore represent **six unique 3,000-row tables**, not twelve independent scientific replications. The retained-stage evaluations verify reproducible execution and honest no-change recording; they show **no revision improvement**. The decision not to invent a precision-weighted correction from mismatched source populations is defensible, but must not be reported as an empirically demonstrated optimization mechanism.

What this case supports is narrower and still relevant: an Agent-generated, externally evidenced model can produce a complete cohort without target individual-level input and preserve three selected direction-level analytical conclusions across fixed seeds. What it does not yet support is replacing patient measurement, recovering individual values, reliable effect-size/power calculation, general-purpose use for arbitrary analyses, correct overall target distribution, superiority to another generation method, or a benefit from the revision loop.

## Continue, simplify or stop

**Close the bounded case with a mixed result. Retain the whole-cohort generation use case, simplify the current claims, and stop target-specific adjustment.** The current implementation deserves an auditable feasibility result, including its magnitude/distribution failures. It is not yet a sufficient result for a broad high-quality-data-generation claim or a revision-optimization contribution.

Any next research decision should distinguish a demonstrated use (selected directional analysis under stated assumptions) from an untested extension (effect-size portability, uncertainty, additional variable types or better general generation). It would require separate authorization/design and genuinely new locked evidence. This review does not initiate another case. The revealed target, frozen candidates, primary report and independent report remain unchanged.
